<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826992</url>
  </required_header>
  <id_info>
    <org_study_id>V2-MA-1801</org_study_id>
    <nct_id>NCT03826992</nct_id>
  </id_info>
  <brief_title>Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia</brief_title>
  <official_title>A Phase I Study of Venetoclax Combined With Vyxeos (CPX-351) for Children, Adolescents and Young Adults With Relapsed or Refractory Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and tolerability of combining venetoclax with Vyxeos
      (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not
      responded to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-institution Phase I pilot study designed to test the safety and tolerability
      of combining venetoclax with Vyxeos (CPX-351, cytarabine and daunorubicin liposome) for the
      treatment of relapsed/refractory acute leukemia in young patients. Subjects will receive a
      single course of study therapy consisting of daily, oral venetoclax at an assigned dose level
      with a 3-day ramp-up to target dose and Vyxeos administered intravenously at the established
      dose on Days 1, 3, and 5. In addition to safety and tolerability, the overall response rate
      to these therapies will be estimated. Pharmacokinetic (PK) analysis will also be conducted to
      define the drug clearance of venetoclax in this combination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of combining venetoclax and Vyxeos (dose limiting toxicities)</measure>
    <time_frame>28 days</time_frame>
    <description>If 2 or more participants have dose limiting toxicities at a given dose level, the maximum tolerated dose will have been exceeded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related toxicities</measure>
    <time_frame>60 days</time_frame>
    <description>Number of related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease response</measure>
    <time_frame>42 days</time_frame>
    <description>Estimate of overall response rate (ORR) defined as (CR/CRi/CRp).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer therapeutics-related cardiac dysfunction (CTRCD) in patients who have previously received anthracyclines</measure>
    <time_frame>60 days</time_frame>
    <description>Measured by echocardiogram (ECHO)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Venetoclax and Vyxeos combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax will be given orally on Days 1-21 per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 21 doses of venetoclax will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.
Venetoclax is given daily by mouth per assigned dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vyxeos</intervention_name>
    <description>Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.</description>
    <arm_group_label>Venetoclax and Vyxeos combination</arm_group_label>
    <other_name>cytarabine and daunorubicin liposome, CPX-351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax Dose:
Dose Level 0 - 400 mg daily for 21 days
Dose Level -1 - 400 mg daily for 14 days</description>
    <arm_group_label>Venetoclax and Vyxeos combination</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 1-39 years

          -  Diagnosis of one of the following:

               -  Acute myeloid leukemia (AML)

               -  Acute undifferentiated leukemia (AUL)

               -  Mixed phenotype acute leukemia (MPAL)

               -  T-cell acute lymphoblastic leukemia (T ALL)

               -  Early thymocyte precursor (ETP) ALL

               -  KMT2A-rearranged ALL

          -  Disease status

               -  Relapsed/Refractory AML, MPAL and AUL

               -  Relapsed/Refractory KMT2A-rearranged ALL, T-cell ALL, ETP ALL

          -  Karnofsky/ Lanksy performance level score of greater than or equal to 50 percent

          -  Prior therapy requirements

               -  Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant
                  (HSCT) or Anthracycline Exposure

               -  14 days must have elapsed since the completion of systemic cytotoxic therapy
                  other than hydroxyurea, decitabine or azacitidine

               -  2 weeks must have elapsed for local palliative radiotherapy (RT); 6 months must
                  have elapsed if prior craniospinal RT or if 50% radiation of pelvis, and at least
                  6 weeks must have elapsed if other substantial bone marrow radiation

          -  Adequate renal, liver, cardiac and central nervous system (CNS) function

        Exclusion Criteria:

          -  Diagnosis of one of the following:

               -  Acute Promyelocytic Leukemia (APML)

               -  Acute leukemia with CNS status 3 involvement

               -  Philadelphia chromosome positive leukemia (Ph+ ALL, MPAL, or AUL)

               -  Fanconi Anemia, Shwachman-Diamond syndrome, or any other bone marrow failure
                  syndrome or DNA repair disorder

               -  Wilson's Disease or other copper-metabolism disorder

          -  Pregnant or breastfeeding

          -  Uncontrolled infection

          -  Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum

          -  Unable to swallow tablets

          -  Receipt of growth factors within 7 days prior to enrollment

          -  Currently receiving another investigational drug

          -  Currently receiving anti-cancer agents (with the exception of intrathecal (IT) agents
             or hydroxyurea)

          -  Unable to comply with the safety monitoring requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Absalon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Agresta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Site Pulblic Contact</last_name>
    <phone>513-636-2799</phone>
    <email>cancer@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>513-636-2799</phone>
      <email>cancer@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Absalon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Agresta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cincinnatichildrens.org/research/divisions/c/cbdi/default/</url>
    <description>Cincinnati Children's Cancer and Blood Diseases Institute</description>
  </link>
  <link>
    <url>http://www.cincinnatichildrens.org/research/divisions/o/oncology/default/</url>
    <description>Cincinnati Children's Hospital Oncology Division</description>
  </link>
  <link>
    <url>http://www.cincinnatichildrens.org/service/l/leukemia-lymphoma/clinical-trials/</url>
    <description>Leukemia and Lymphoma Program</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>Vyxeos</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>acute myeloid leukemia, childhood</keyword>
  <keyword>mixed-lineage leukemia (MLL)</keyword>
  <keyword>AML</keyword>
  <keyword>CPX-351</keyword>
  <keyword>Venclexta</keyword>
  <keyword>Histone-lysine N-methyltransferase 2A (KmT2A)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

